Tharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy

MT Newswires Live

2024/10/30

Tharimmune (THAR) shares climbed by more than 130% in recent Wednesday trading after the company said it received "positive feedback" from the European Medicines Agency about TH104, its candidate to treat moderate-to-severe pruritus in primary biliary cholangitis, or PBC.

The feedback came in a Scientific Advice meeting, the company said, where the agency provided guidance on a planned phase 2 trial to advance TH104.

The agency noted that there was no need to conduct additional animal studies and considered human exposure adequate to move forward, the company added.

Tharimmune said it plans to start a phase 2 multiple-ascending dose trial in the coming months to evaluate the safety and tolerability of TH104, and expects topline data in 2025.

Price: 4.46, Change: +2.44, Percent Change: +120.79

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2479733406"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2479733406\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2479733406?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 23:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479733406","market":"fut","top_or_hot":-1,"title":"Tharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy","media":"MT Newswires Live","content":"<html><body><p> Tharimmune (THAR) shares climbed by more than 130% in recent Wednesday trading after the company said it received \"positive feedback\" from the European Medicines Agency about TH104, its candidate to treat moderate-to-severe pruritus in primary biliary cholangitis, or PBC.</p><p>The feedback came in a Scientific Advice meeting, the company said, where the agency provided guidance on a planned phase 2 trial to advance TH104.</p><p>The agency noted that there was no need to conduct additional animal studies and considered human exposure adequate to move forward, the company added.</p><p>Tharimmune said it plans to start a phase 2 multiple-ascending dose trial in the coming months to evaluate the safety and tolerability of TH104, and expects topline data in 2025.</p><p>Price: 4.46, Change: +2.44, Percent Change: +120.79</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-10-30 23:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Tharimmune (THAR) shares climbed by more than 130% in recent Wednesday trading after the company said it received \"positive feedback\" from the European Medicines Agency about TH104, its candidate to treat moderate-to-severe pruritus in primary biliary cholangitis, or PBC.</p><p>The feedback came in a Scientific Advice meeting, the company said, where the agency provided guidance on a planned phase 2 trial to advance TH104.</p><p>The agency noted that there was no need to conduct additional animal studies and considered human exposure adequate to move forward, the company added.</p><p>Tharimmune said it plans to start a phase 2 multiple-ascending dose trial in the coming months to evaluate the safety and tolerability of TH104, and expects topline data in 2025.</p><p>Price: 4.46, Change: +2.44, Percent Change: +120.79</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2479733406","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479733406","pubTimestamp":1730300791,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tharimmune  shares climbed by more than 130% in recent Wednesday trading after the company said it received \"positive feedback\" from the European Medicines Agency about TH104, its candidate to treat moderate-to-severe pruritus in primary biliary cholangitis, or PBC.The feedback came in a Scientific Advice meeting, the company said, where the agency provided guidance on a planned phase 2 trial to advance TH104.The agency noted that there was no need to conduct additional animal studies and considered human exposure adequate to move forward, the company added.Tharimmune said it plans to start a phase 2 multiple-ascending dose trial in the coming months to evaluate the safety and tolerability of TH104, and expects topline data in 2025.Price: 4.46, Change: +2.44, Percent Change: +120.79","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技"},"translate_title":"由于EMA对潜在瘙痒疗法的积极反馈，Tharimmune股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"THAR":0.9},"content_text":"Tharimmune (THAR) shares climbed by more than 130% in recent Wednesday trading after the company said it received \"positive feedback\" from the European Medicines Agency about TH104, its candidate to treat moderate-to-severe pruritus in primary biliary cholangitis, or PBC.The feedback came in a Scientific Advice meeting, the company said, where the agency provided guidance on a planned phase 2 trial to advance TH104.The agency noted that there was no need to conduct additional animal studies and considered human exposure adequate to move forward, the company added.Tharimmune said it plans to start a phase 2 multiple-ascending dose trial in the coming months to evaluate the safety and tolerability of TH104, and expects topline data in 2025.Price: 4.46, Change: +2.44, Percent Change: +120.79","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}